Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs FLX 925 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Flexus Biosciences; FLX Bio
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 21 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 03 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top